• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Immunology Letters >Safety and immunogenicity of a gE/gI/TK gene-deleted pseudorabies virus variant expressing the E2 protein of classical swine fever virus in pigs
【24h】

Safety and immunogenicity of a gE/gI/TK gene-deleted pseudorabies virus variant expressing the E2 protein of classical swine fever virus in pigs

机译：表达经典猪瘟病毒E2蛋白的gE / gI / TK基因缺失的伪狂犬病病毒变异体的安全性和免疫原性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Classical swine fever (CSF) and pseudorabies (PR) are both major infectious diseases of pigs, causing enormous economic losses to the swine industry in many countries. A marker vaccine that enables differentiation of infected from vaccinated animals (DIVA) is highly desirable for control and eradication of these two diseases in endemic areas. Since late 2011, PR outbreaks have been frequently reported in many Bartha-K61-vaccinated pig farms in China. It has been demonstrated that a pseudorabies virus (PRV) variant with altered antigenicity and increased pathogenicity was responsible for the outbreaks. Previously, we showed that rPRVTJ-delgE/gI/TK, a gE/gl/TK-deleted PRV variant, was safe for susceptible animals and provided a complete protection against lethal PRV variant challenge, indicating that rPRVTJ-delgE/gI/TK can be used as an attractive vaccine vector. To develop a safe bivalent vaccine against CSF and PR, we generated a recombinant virus rPRVTJ-delgE/gI/TK-E2 expressing the E2 protein of classical swine fever virus (CSFV) based on rPRVTJ-delgE/gI/TK and evaluated its safety and immunogenicity in pigs. The results indicated that pigs (n=5) immunized with rPRVTJ-delgE/gI/TK-E2 of different doses did not exhibit clinical signs or viral shedding following immunization, the immunized pigs produced anti-PRV or anti-CSFV neutralizing antibodies and the pigs immunized with 10(6) or 10(6) TCID50 rPRVTJ-delgE/gl/TK-E2 were completely protected against the lethal challenge with either CSFV Shimen strain or variant PRV TJ strain. These findings suggest that rPRVTJ-delgE/gI/TK-E2 is a promising bivalent DIVA vaccine candidate against CSFV and PRV coinfections. (C) 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
机译：古典猪瘟（CSF）和伪狂犬病（PR）都是猪的主要传染病，在许多国家给养猪业造成了巨大的经济损失。对于在流行地区控制和根除这两种疾病而言，非常需要一种能够区分感染疫苗动物（DIVA）的标记疫苗。自2011年下半年以来，中国许多Bartha-K61疫苗接种猪场经常爆发PR暴发。已经证明具有改变的抗原性和增加的致病性的伪狂犬病病毒（PRV）变体是爆发的原因。以前，我们表明，rPRVTJ-delgE / gI / TK（gE / gl / TK缺失的PRV变异体）对于易感动物是安全的，并提供了针对致命PRV变异体攻击的全面保护，表明rPRVTJ-delgE / gI / TK可以用作有吸引力的疫苗载体。为了开发针对CSF和PR的安全二价疫苗，我们基于rPRVTJ-delgE / gI / TK生成了表达经典猪瘟病毒（CSFV）E2蛋白的重组病毒rPRVTJ-delgE / gI / TK-E2，并评估了其安全性和猪的免疫原性。结果表明，用不同剂量的rPRVTJ-delgE / gI / TK-E2免疫的猪（n = 5）在免疫后没有临床症状或病毒脱落，被免疫的猪产生了抗PRV或抗CSFV中和抗体，并且用CSFV Shimen株或PRV TJ变异株完全保护免受10（6）或10（6）TCID50 rPRVTJ-delgE / gl / TK-E2免疫的猪。这些发现表明，rPRVTJ-delgE / gI / TK-E2是针对CSFV和PRV合并感染的有前途的二价DIVA疫苗候选人。 （C）2016年欧洲免疫学会联合会。由Elsevier B.V.发布。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号